by @JTC_PALIdev | Feb 13, 2024 | Press Releases
– Company announces strategic streamlining of Board to align with the current state of clinical development and corporate vision – Advancement of PALI-2108 for the treatment of moderate-to-severe ulcerative colitis (UC) toward Phase 1 clinical study; first...
by @JTC_PALIdev | Feb 8, 2024 | Press Releases
Carlsbad, CA, Feb. 08, 2024 — Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the “Company”), a biopharmaceutical company focused on developing novel therapeutics for serious chronic gastrointestinal (GI) diseases, today announced a...
by @JTC_PALIdev | Feb 8, 2024 | Press Releases
Bruce Sands, MD, MS., Dr. Burrill B. Crohn Professor of Medicine, Icahn School of Medicine at Mount Sinai and System Chief, Division of Gastroenterology, Mount Sinai Health SystemFlorian Rieder, MD, Associate Staff in the Department of Gastroenterology, Hepatology,...
by @JTC_PALIdev | Jan 30, 2024 | Press Releases
Carlsbad, CA, Jan. 30, 2024 — Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the “Company”), a biopharmaceutical company focused on developing novel therapeutics for serious chronic gastrointestinal (GI) diseases, today announced an...
by @JTC_PALIdev | Jan 29, 2024 | Press Releases
– Preclinical data demonstrated PALI-2108 to be safe and well tolerated – PALI-2108 is orally delivered and colon activated allowing for local activity with low systemic exposure – Company advancing PALI-2108 for the treatment of moderate-to-severe...
by @JTC_PALIdev | Jan 9, 2024 | Press Releases
Carlsbad, CA, Jan. 09, 2024 — Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the “Company”), a biopharmaceutical company focused on developing novel therapeutics for serious chronic gastrointestinal (GI) diseases, today announced that...
